Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Table 1 Induction and mobilization therapy

Induction protocol	Dose	Application	Treatment days
(isatuximab)-RVd (21 days/cycle, 6 cycles)
(Isatuximab)	10 mg/kg	iv	cycle 1: 1, 8, 15 cycle 2: 1, 8 cycle 3, 5: 1, 15 cycle 4, 6: 1
Lenalidomide	25 mg	po	1–14
Bortezomib	1.3 mg/qm	sc	1, 4, 8, 11
Dexamethasone	20 mg	po	cycle 1,3,5: 1, 2, 4, 5, 8, 9, 11, 12, 15 cycle 2,4,6: 1, 2, 4, 5, 8, 9, 11, 12
(elotuzumab)-RVd (21 days/cycle, 4 cycles)
(Elotuzumab)	10 mg/kg	iv	cycle 1: 1, 8, 15 cycle 3–4: 1, 11
Lenalidomide	25 mg	po	1–14
Bortezomib	1.3 mg/qm	sc	1, 4, 8, 11
Dexamethasone	20 mg	po	1, 2, 4, 5, 8, 9, 11, 12, 15,
Mobilization protocol
CAD (28 days/cycle, 1 cycle)
Cyclophosphamide	1000 mg/qm	iv	1
Doxorubicin	15 mg/qm	Iv	1–4
G-CSF	10 µg/kg bw	iv	9,10,11,12,13,14
Cyclophosphamide mono (28 days/cycle, 1 cycle)
Cyclophosphamide	1000 mg/qm	iv	1,2
G-CSF	10 µg/kg bw	iv	9,10,11,12,13,14

G-CSF Granulocyte colony-stimulating factor, iv Intravenous, po Per os, qm Square meter, sc Subcutaneous, RVd Lenalidomide, bortezomib, dexamethasone

ISSN: 1471-2407